Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
NCT07222878Phase 1Completed
- Sponsor
- NeuroPro Therapeutics
- Start
- Sep 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NPT-2042 in epilepsy and Alzheimer's disease (AD) (3 cohorts), sponsored by NeuroPro Therapeutics. Primary endpoints: Single dose pharmacokinetic parameters at Day 7 and Relative Bioavailability (Frel) at Day 4. Started Sep 2025; status: completed.
02
Drugs
NPT-2042
03
Conditions
epilepsyAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07222878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222878.